40 Heart Attack Clinical Trials in Columbus, GA (2026)

Q: How do I join a clinical trial in Columbus?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbus research site will contact you.

Recruiting Heart Attack Studies in Columbus

NCT02560883Recruiting

Hairy Cell Leukemia Patient Data Registry

The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life...

Columbus, GA5,000 participantsOhio State University Comprehensive Cancer Center

View Study Details

NCT04573660Recruiting

Abbott Vascular Medical Device Registry

The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scop...

Columbus, GA3,784 participantsAbbott Medical Devices

View Study Details

NCT01522183Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab....

Columbus, GA3,000 participantsAlexion Pharmaceuticals, Inc.

View Study Details

NCT06854458Recruiting

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the h...

Columbus, GANA1,000 participantsBrigham and Women's Hospital

View Study Details

NCT07154823Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient co...

Columbus, GA550 participantsTempus AI

View Study Details

NCT06351631Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...

Columbus, GAPHASE3400 participantsMerck Sharp & Dohme LLC

View Study Details

NCT03802695Recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transpla...

Columbus, GAPHASE1300 participantsOrca Biosystems, Inc.

View Study Details

NCT06933472Recruiting

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lo...

Columbus, GAPHASE3264 participantsAlebund Pharmaceuticals

View Study Details

NCT05475925Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular ...

Columbus, GAPHASE1200 participantsDren Bio

View Study Details

NCT02387255Recruiting

Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

The main objective of this study is to utilize Magnetic Resonance Elastography (MRE) to determine tissue stiffness of abdominal aortic aneurysms (AAA). For patients with AAA, MRE is a more sensitive a...

Columbus, GA165 participantsOhio State University

View Study Details

NCT06969430Recruiting

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary obj...

Columbus, GAPHASE1154 participantsDebiopharm International SA

View Study Details

NCT06576271Recruiting

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy pa...

Columbus, GAPHASE1142 participantsGlaxoSmithKline

View Study Details

NCT05401097Recruiting

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

This phase II study compares the order of treatment with ivosidenib or enasidenib and azacitidine plus venetoclax in treating older patients with acute myeloid leukemia with genetic changes in the IDH...

Columbus, GAPHASE2125 participantsAlice Mims

View Study Details

NCT07249346Recruiting

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myelo...

Columbus, GAPHASE2124 participantsHannah Choe, MD

View Study Details

NCT07271667Recruiting

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL....

Columbus, GAPHASE2108 participantsCuris, Inc.

View Study Details

NCT06561360Recruiting

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People with Hairy Cell Leukemia (HCL)

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will...

Columbus, GAPHASE286 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06233318Recruiting

Sternotomy PIFB Block in Open Heart Surgery

The purpose of this study is to evaluate if the use of a bilateral nerve block with a local anesthetic (ropivacaine), as part of a standard of care pain control regimen (called multimodal analgesia \[...

Columbus, GANA84 participantsOhio State University

View Study Details

NCT05417165Recruiting

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leuke...

Columbus, GAPHASE280 participantsSeema Bhat

View Study Details

NCT06707493Recruiting

Ivosidenib as Post-HSCT Maintenance for AML

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell tran...

Columbus, GAPHASE275 participantsMassachusetts General Hospital

View Study Details

NCT07604974Recruiting

A Study to Assess the Safety, Tolerability and Efficacy of ION775

The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG)....

Columbus, GAPHASE272 participantsIonis Pharmaceuticals, Inc.

View Study Details

NCT06757647Recruiting

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This phase II trial tests how well acalabrutinib works in treating patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and evaluates how treatment with acalabrutinib affe...

Columbus, GAPHASE261 participantsSeema Bhat

View Study Details

NCT06582615Recruiting

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

The goal of this randomized clinical trial is to learn if a healthy eating pattern called the MIND eating plan can reduce cancer-related cognitive impairment (commonly called "chemobrain") and other s...

Columbus, GANA60 participantsOhio State University Comprehensive Cancer Center

View Study Details

NCT06651970Recruiting

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice daily \[bd\]) compared to investigator's...

Columbus, GAPHASE460 participantsAstraZeneca

View Study Details

NCT05422794Recruiting

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatm...

Columbus, GAPHASE157 participantsNational Cancer Institute (NCI)

View Study Details

NCT05418088Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of ...

Columbus, GAPHASE154 participantsSumithira Vasu

View Study Details

NCT03874052Recruiting

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and aza...

Columbus, GAPHASE151 participantsJennifer Saultz

View Study Details

NCT07685717Recruiting

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib,...

Columbus, GAPHASE250 participantsJennifer Woyach

View Study Details

NCT05417308Recruiting

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

This early phase I trial studies the possible benefits and/or side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast ca...

Columbus, GAEARLY_PHASE150 participantsOhio State University Comprehensive Cancer Center

View Study Details

NCT03104491Recruiting

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects ...

Columbus, GAPHASE144 participantsLeland Metheny

View Study Details

NCT06026657Recruiting

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

This phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal donor TGFBi NK cells with or without naxitamab work for the treatment of patients w...

Columbus, GAPHASE142 participantsMargaret Gatti-Mays

View Study Details

NCT05677802Recruiting

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

This clinical trial aims to see if patients with triple negative breast cancer can complete a biobehavioral stress reduction program that also addresses health related social needs (e.g., utilities, t...

Columbus, GANA40 participantsOhio State University Comprehensive Cancer Center

View Study Details

NCT03533816Recruiting

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimi...

Columbus, GAPHASE138 participantsUniversity of Kansas Medical Center

View Study Details

NCT06466122Recruiting

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite t...

Columbus, GAPHASE230 participantsKerry Rogers

View Study Details

NCT05592015Recruiting

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the...

Columbus, GAPHASE230 participantsJonathan Brammer

View Study Details

NCT04049539Recruiting

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabi...

Columbus, GAPHASE128 participantsOhio State University Comprehensive Cancer Center

View Study Details

NCT06440135Recruiting

Ziftomenib Maintenance Post Allo-HCT

The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoiet...

Columbus, GAPHASE122 participantsMassachusetts General Hospital

View Study Details

NCT07061951Recruiting

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (...

Columbus, GAPHASE220 participantsNational Cancer Institute (NCI)

View Study Details

NCT05503134Recruiting

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 1-24.99 with relapsed or refractory ...

Columbus, GAPHASE120 participantsNationwide Children's Hospital

View Study Details

NCT06340750Recruiting

BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypo...

Columbus, GAPHASE118 participantsLuminary Therapeutics

View Study Details

NCT04848064Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell ...

Columbus, GAPHASE112 participantsJohn Reneau

View Study Details

About Heart Attack Clinical Trials in Columbus

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 40 heart attack clinical trials recruiting participants in Columbus, GA. These studies are seeking a combined 16,500 participants. Research is being sponsored by Ohio State University Comprehensive Cancer Center, Abbott Medical Devices, Alexion Pharmaceuticals, Inc. and 29 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Columbus — FAQ

Are there heart attack clinical trials in Columbus?

Yes, there are 40 heart attack clinical trials currently recruiting in Columbus, GA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Columbus?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbus research site will contact you about next steps.

Are clinical trials in Columbus free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Columbus studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 40 active trials in Columbus are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated September 5, 2026 from ClinicalTrials.gov